




RealRate

PHARMACEUTICAL 2022

Aprea Therapeutics Inc
Rank 205 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Aprea Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aprea Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 70% points. The greatest weakness of Aprea Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is 316%, being 41% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	56,584
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,316
Liabilities, Non-Current	0
Other Assets	215
Other Compr. Net Income	-322
Other Expenses	0
Other Liabilities	0
Other Net Income	319
Other Revenues	0
Property and Equipment	24
Research and Development	23,896
Selling, General and Administrative Expense	13,550

Output Variable	Value in 1000 USD
Assets	56,823
Liabilities	7,316
Expenses	37,446
Revenues	0
Stockholders Equity	49,507
Net Income	-37,127
Comprehensive Net Income	-37,288
BaseVar	51,114
ECR before LimitedLiability	220%
Economic Capital Ratio	316%